** India's pharmaceutical companies .NIPHARM drop 1.7%,
with 19 of the 20 constituents trading in the red
** The index has lost about 7.6% over two weeks, pressured
by the uncertainty over U.S. tariffs following President Donald
Trump's plans to levy at least 25% tariff on pharmaceutical
imports
** The United States is India's biggest pharmaceuticals
market
** Domestic drugmakers are hoping that discussions between
the U.S. and India will help them steer clear of Trump's tariff
threat, a trade association says
** Indian pharma companies to remain volatile and could see
further pressure due to U.S. tariff, says Citi Research
** Citi prefers drugmakers such as Divi's Laboratories
DIVI.NS , Sun Pharma SUN.NS and Torrent Pharma TORP.NS
with lower exposure to U.S. generics
** The pharma index is down 2% for the week, against the
Nifty's 0.6% drop, making it one of the worst-performing sectors
(Reporting by Bharath Rajeswaran in Bengaluru)
((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))